![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
BAX has a long history as a leader in the medical supply business but is taking big steps into biotech through acquisitions and research, and is looking to expand it's international presence. Baxter is also the current leader in the race to bring a human blood substitute to market (HemAssist)for use in trauma and surgery. It should be introduced in Europe early in 1998. BAX, with a current yield of 2.6%, appears to be a real value at this point. Other opinions??? | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |